Elsilimomab  (Synonyms: B-E8; Anti-IL-6 MAB B-E8)

Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a K_D of 22 pM and an IC₅₀ of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)^[1][2][3].

Elsilimomab specifically inhibits IL-6 but not LIF (leukemia inhibitory factor)-induced cell growth^[2].
Elsilimomab (20 μg/mL) neutralizes human IL-6^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145960.00

468715-71-1

Liquid

Colorless to light yellow

[Elsilimomab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-6 Protein, Human can bind Elsilimomab. The EC₅₀ for this effect is 32.74 ng/mL.

• [1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265.  [Content Brief]

  [2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390.  [Content Brief]

  [3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.  [Content Brief]